Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fidrisertib (IPN60130) in Fibrodysplasia Ossificans Progressiva
NCT05039515Phase 2Terminated
- Sponsor
- Clementia Pharmaceuticals Inc.
- Start
- Dec 2021
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 2 trial of Fidrisertib in fibrodysplasia ossificans progressiva (FOP), sponsored by Clementia Pharmaceuticals Inc.. Started Dec 2021; status: terminated.
02
Drugs
Fidrisertib
03
Conditions
fibrodysplasia ossificans progressiva (FOP)
Beyond the preview
Go deeper on NCT05039515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05039515.